SCHEMBL5089465

SCHEMBL5089465

CCOC(=O)Nc1ccc(OCc2ccc(C)cc2)cc1N

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.53
KCNQ2 O43526 3/20 0.53
KCNQ3 O43525 2/20 0.53
KCNQ4 P56696 1/20 0.53
KCNQ5 Q9NR82 1/20 0.53
ALDH1A1 P00352 2/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
PARP10 Q53GL7 1/20 0.48
MAOB P27338 3/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
LNPEP Q9UIQ6 1/20 0.44
FFAR1 O14842 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5087377 0.91 MAOA (0.52) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2
SCHEMBL5090811 0.91 KCNQ2 (0.65) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2
SCHEMBL5090320 0.90 ALDH1A1 (0.53) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2
SCHEMBL5090177 0.89 KCNQ2 (0.49) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2
SCHEMBL5089204 0.89 LNPEP (0.55) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2
SCHEMBL5089259 0.88 MAOB (0.52) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2
SCHEMBL5087380 0.88 KCNQ2 (0.57) CYP1A2CYP2C9CYP2C19KCNQ2KCNQ3
SCHEMBL5090265 0.88 RAB9A (0.51) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2
SCHEMBL5090792 0.87 KCNQ2 (0.55) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2
SCHEMBL5090790 0.86 KCNQ2 (0.49) CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188561-A1 N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS JPMORGAN CHASE BANK, N.A. 2008-08-07 US claimed
US-8722929-B2 N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators VALEANT PHARMACEUTICALS INTERNATIONAL (US) 2014-05-13 US disclosed
US-20080188561-A1 N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS JPMORGAN CHASE BANK, N.A. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188561-A1 N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS KCNB2, KCNJ2, KCNA2 CYP1A2 525/4885CYP2C9 895/4885CYP2C19 1030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.